Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)
Status:
Withdrawn
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral
therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability
of 2 doses of GW823093, compared to placebo, taken once daily in patients with Type 2
diabetes mellitus.